SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

FSD Pharma Inc. – ‘6-K’ for 2/7/23

On:  Tuesday, 2/7/23, at 8:30am ET   ·   For:  2/7/23   ·   Accession #:  1157523-23-188   ·   File #:  1-39152

Previous ‘6-K’:  ‘6-K’ on / for 1/30/23   ·   Next:  ‘6-K’ on / for 2/14/23   ·   Latest:  ‘6-K’ on 5/7/24 for 5/6/24   ·   1 Reference:  By:  FSD Pharma Inc. – ‘424B5’ on 2/20/24

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/07/23  FSD Pharma Inc.                   6-K         2/07/23    2:21K                                    Business Wire/FA

Current, Quarterly or Annual Report by a Foreign Issuer   —   Form 6-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Fsd Pharma Inc. 6-K                                 HTML     10K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     14K

‘6-K’   —   Fsd Pharma Inc. 6-K

This is an HTML Document rendered as filed.  [ Alternative Formats ]

 C: 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of: February 2023

Commission File Number: 001-39152

FSD PHARMA INC.
(Translation of registrant’s name into English)

199 Bay St., Suite 4000
Toronto, Ontario M5L 1A9, Canada
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____



SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 

 
FSD Pharma Inc.
 
(Registrant)
 
 
 
 
 
 
Date:  February 7, 2023 
By:
 
 
Nathan Coyle, Chief Financial Officer

EXHIBIT INDEX
 
 
 
 
Exhibit
Description
 
 
Exhibit 99.1

Dates Referenced Herein

This ‘6-K’ Filing    Date    Other Filings
Filed on / For Period end:2/7/23None on these Dates
 List all Filings 

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/20/24  FSD Pharma Inc.                   424B5       2/16/24    1:863K                                   RDG Filings/FA
↑Top
Filing Submission 0001157523-23-000188   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Tue., May 14, 5:08:00.1am ET